• CMEVIDEO

  • On the Scene at ADA 2012: Interview with Jack L. Leahy, MD - GLP-1 agonists as monotherapy and in combination with insulin

    Earn CME Credit »
  • Author(s)/Faculty: Jack L. Leahy, MD
    Source: Education Lab
    Type: Multimedia Articles/Items: 1
    Release Date: 6/13/2012 Expiration Date: 6/12/2013
    Credit Type: CME Number of Credit(s): 0.25
    Cost: Free Provider: Vindico Medical Education

  • The incretin-based therapies, including GLP-1 receptor agonists and DPP-4 inhibitors, have been shown to offer a number of beneficial cardiovascular and lipid effects in addition to enhancing glycemic control in patients with type 2 diabetes, and may be of benefit in preventing beta cell deterioration. GLP-1 agonists, in additional to these favorable effects, can result in weight reduction and appetite suppression. A new longer-acting formulation of exenatide, in addition to providing these benefits, may also improve adherence by being less onerous than daily injections for patients. Some incretin-based therapies are approved for use with insulin – exenatide with insulin glargine and liraglutide with insulin levimir – and there is increasing evidence about the advantages of this combination therapy.

Sponsorship Statement: This continuing medical education activity is sponsored by Vindico Medical Education.

Support Statement: This activity is supported by an educational grant from

Target Audience: The intended audience for the activities is Endocrinologists, Cardiologists, Diabetologists, Certified Diabetes Educators and other healthcare professionals involved in the treatment of patients with diabetes.

Learning Objectives: At the conclusion of this activity participants should be able to:

  1. Assess the role of GLP-1 on the cardiovascular system and the potential role of GLP-1-based therapies in reducing cardiometabolic risk.
  2. Apply evidence-based data on the use of GLP-1 agonists in combination with insulin to effectively treat type 2 diabetes.
  3. Assess longer acting GLP-1 agonists for their ability to achieve HbA1C targets and minimize adverse events that may affect adherence to therapy.

Faculty:
Jack L. Leahy, MD
Professor of Medicine
Chief, Division of Endocrinology, Diabetes and Metabolism
University of Vermont
Burlington, Vermont

Robert R. Henry, MD (Planning Committee)
Professor of Medicine
University of California
San Diego, California

External Reviewer:
Ronald Codario, MD, FACP, FNLA
Carol H. Wysham, MD

Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:
Vindico Medical Education designates this Enduring Material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, June 13, 2012 to June 12, 2013.

How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, read the articles, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering two (2) out of three (3) of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™.

Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Planning Committee and Faculty members report the following relationship(s):
Jack L. Leahy, MD
Salary: Takeda (Research Grant)
Consulting Fees: Sanofi, Novo Nordisk, Bristol Meyers Squibb, Janssen, Takeda

Robert R. Henry, MD (Planning Committee)
Consulting Fees: Amylin, Novo Nordisk, Sanofi, Merck, Boehringer Ingelheim, Intarcia
Contracted Research: Amylin, Novo Nordisk, Sanofi, Lilly, Bristol Meyers Squibb, AstraZeneca

External Reviewer reports the following relationship(s):
Ronald Codario, MD, FACP, FNLA
No relevant financial relationships to disclose.

Carol H. Wysham, MD
Consulting Fees: Amylin, Boehringer Ingelheim, Johnson & Johnson
Fees for Non-CME Services: Amylin, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, Sanofi Aventis
Contracted Research: Amylin, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, Sanofi Aventis, Intarcia, Biodel

Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2012 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.